First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
ConclusionRIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2− ABC.
Conclusions: Study results indicate that, for patients and caregivers, pd health states are associated with a deterioration of qol and utility and a decrease in productivity in both 1l and ≥2l. PMID: 30111973 [PubMed - in process]
CONCLUSIONS: Abemaciclib is an effective and well-tolerated treatment for HR-positive, HER2-negative advanced or metastatic breast cancer. PMID: 30099886 [PubMed - as supplied by publisher]
ConclusionsHRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2 − advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population.
Conclusions: Fulvestrant showed encouraging clinical activity and favorable feasibility in postmenopausal women with MBC who had been treated with multiple endocrine therapies and/or cytotoxic chemotherapies. PMID: 29540055 [PubMed - as supplied by publisher]
This article summarizes FDA decision-making and data supporting the neratinib approval. PMID: 29523624 [PubMed - as supplied by publisher]
This article summarizes FDA decision-making and data supporting the approval of ribociclib. PMID: 29437768 [PubMed - as supplied by publisher]
ConclusionsFulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials.
We present an analysis of patient reports of these symptoms over the course of the trial, with fatigue as the central concept. We explicitly consider missing data, the relationships between symptoms, and the relationships with survival.
CONCLUSIONS: SC trastuzumab is preferred by patients and the nursing staff versus the IV administration. The use of SC trastuzumab reduced the cost derived from trastuzumab administration. PMID: 28534353 [PubMed - in process]
Purpose: Radiation therapy is an important treatment modality in the curative management of early stage breast cancer. With increasing cancer survivorship, late effects of cancer treatment have become increasingly relevant. Breast fibrosis is a common late effect following therapeutic irradiation which can potentially result in pain, poor cosmesis, and functional impairment. Randomized trials have suggested that radiation fibrosis may be reversible or preventable using a medication regimen of Pentoxifylline and Vitamin E. These clinical trials have shown excellent patient compliance and tolerability of this regimen, but it...